Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 5:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 280 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adenocarcinoma of Rectum Clear all
Completed Phase 1 Interventional

RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma

NCT00101972
View directory record Official record
Conditions
Cancer
Interventions
monoclonal antibody RAV12
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Jul 24, 2026, 5:26 AM EDT
Completed Phase 2 Interventional

Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer

NCT00258232
View directory record Official record
Conditions
Colorectal Cancer
Interventions
capecitabine, celecoxib, irinotecan hydrochloride
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
3
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2013 · Synced Jul 24, 2026, 5:26 AM EDT
Terminated Phase 2 Interventional

SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

NCT00006001
View directory record Official record
Conditions
Colorectal Cancer
Interventions
semaxanib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
10
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2013 · Synced Jul 24, 2026, 5:26 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Young-Onset Colorectal Cancer

NCT02863107
View directory record Official record
Conditions
Colon Adenocarcinoma, Colorectal Carcinoma, Rectal Adenocarcinoma
Interventions
Biospecimen Collection, Medical Chart Review, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
818 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2030
U.S. locations
5
States / cities
Conroe, Texas • Houston, Texas • League City, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 24, 2026, 5:26 AM EDT
Active, not recruiting Early Phase 1 Interventional

Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma

NCT05108428
View directory record Official record
Conditions
Rectal Adenocarcinoma
Interventions
Capecitabine, Radiation Therapy, FOLFOX regimen
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 24, 2026, 5:26 AM EDT
Terminated Phase 2 Interventional

BMS-247550 in Treating Patients With Metastatic Colorectal Cancer

NCT00033306
View directory record Official record
Conditions
Colorectal Cancer
Interventions
ixabepilone, Fluoropyrimidine, Irinotecan
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Birmingham, Alabama • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 4, 2013 · Synced Jul 24, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments

NCT00560560
View directory record Official record
Conditions
Colorectal Neoplasm
Interventions
CP-751, 871
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
San Francisco, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2013 · Synced Jul 24, 2026, 5:26 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors

NCT01765790
View directory record Official record
Conditions
Metastatic Adenocarcinoma of the Colon or Rectum, Malignant Solid Tumors
Interventions
Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Scottsdale, Arizona • Sarasota, Florida • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Jul 24, 2026, 5:26 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer

NCT00004102
View directory record Official record
Conditions
Colorectal Cancer
Interventions
FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2011 · Synced Jul 24, 2026, 5:26 AM EDT
Terminated Phase 1 Interventional

Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver

NCT02110953
View directory record Official record
Conditions
Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
irinotecan-eluting beads, hepatic artery embolization
Combination Product · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 25, 2018 · Synced Jul 24, 2026, 5:26 AM EDT
Completed Phase 1 Interventional

Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer

NCT00280176
View directory record Official record
Conditions
Colorectal Cancer
Interventions
bortezomib, fluorouracil, radiation therapy
Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Jul 24, 2026, 5:26 AM EDT
Completed Phase 1 Interventional

Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies

NCT01643499
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Adenocarcinoma of the Gallbladder, Adenocarcinoma of Unknown Primary, Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Diffuse Adenocarcinoma of the Stomach, Duct Cell Adenocarcinoma of the Pancreas, Intestinal Adenocarcinoma of the Stomach, Localized Unresectable Adult Primary Liver Cancer, Metastatic Carcinoma of Unknown Primary, Metastatic Extrahepatic Bile Duct Cancer, Mixed Adenocarcinoma of the Stomach, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Newly Diagnosed Carcinoma of Unknown Primary, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage III Pancreatic Cancer, Stage IIIA Colon Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Gastric Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Gastric Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Gastric Cancer, Stage IIIC Rectal Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer, Stage IVA Colon Cancer, Stage IVA Gallbladder Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Gallbladder Cancer, Stage IVB Rectal Cancer, Unresectable Extrahepatic Bile Duct Cancer
Interventions
oxaliplatin, irinotecan hydrochloride, leucovorin calcium, fluorouracil, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Jul 24, 2026, 5:26 AM EDT
Completed No phase listed Observational

PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study

NCT01751516
View directory record Official record
Conditions
Rectal Carcinoma
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Jul 24, 2026, 5:26 AM EDT
Active, not recruiting Phase 2 Interventional

Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

NCT00335816
View directory record Official record
Conditions
Colorectal Cancer
Interventions
fluorouracil, leucovorin calcium, oxaliplatin, conventional surgery, radiation therapy, laboratory biomarker analysis, DNA analysis, polymerase chain reaction, immunohistochemistry staining method
Drug · Procedure · Radiation + 2 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2026
U.S. locations
14
States / cities
Concord, California • Duarte, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Jul 24, 2026, 5:26 AM EDT
Recruiting No phase listed Observational

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

NCT05059444
View directory record Official record
Conditions
Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma, Rectal Adenocarcinoma
Interventions
Guardant Reveal
Diagnostic Test
Lead sponsor
Guardant Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
33
States / cities
Birmingham, Alabama • Chandler, Arizona • Hot Springs, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Jul 24, 2026, 5:26 AM EDT
Completed Phase 1 Interventional

Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery

NCT03317119
View directory record Official record
Conditions
Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Carcinoma, RAS Family Gene Mutation, Stage III Colon Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7, Stage IIIA Colon Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Colon Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Colon Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7, Stage IV Colon Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Rectal Cancer AJCC v7, Stage IVA Colon Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Colon Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Trametinib, Trifluridine and Tipiracil Hydrochloride
Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
8
States / cities
Corona, California • Duarte, California • Lancaster, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2024 · Synced Jul 24, 2026, 5:26 AM EDT
Completed Phase 2 Interventional

BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer

NCT00022477
View directory record Official record
Conditions
Colorectal Cancer
Interventions
BMS-247550
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
15
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Jul 24, 2026, 5:26 AM EDT
Active, not recruiting Phase 1 Interventional

TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer

NCT04104139
View directory record Official record
Conditions
Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
Interventions
3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Trifluridine and Tipiracil Hydrochloride
Radiation · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 24, 2026, 5:26 AM EDT
Completed Not applicable Interventional

Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care

NCT01726296
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Squamous Cell Lung Cancer, Stage I Colon Cancer, Stage I Rectal Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Colon Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIA Rectal Cancer, Stage IIB Colon Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIB Rectal Cancer, Stage IIC Colon Cancer, Stage IIC Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer
Interventions
educational intervention, medical chart review
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Jul 24, 2026, 5:26 AM EDT
Completed Not applicable Interventional

Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer

NCT00084773
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cetuximab, fluorouracil, neoadjuvant therapy, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Jul 24, 2026, 5:26 AM EDT
Completed Phase 1Phase 2 Interventional

Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer

NCT00004870
View directory record Official record
Conditions
Colorectal Cancer
Interventions
oblimersen sodium, irinotecan hydrochloride
Biological · Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
3
States / cities
Cleveland, Ohio • Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Jul 24, 2026, 5:26 AM EDT
Withdrawn Phase 2 Interventional

Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer

NCT00408772
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
bevacizumab, capecitabine, oxaliplatin, conventional surgery, neoadjuvant therapy, radiofrequency ablation
Biological · Drug · Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Jul 24, 2026, 5:26 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer

NCT00006786
View directory record Official record
Conditions
Colorectal Cancer
Interventions
bevacizumab, fluorouracil, irinotecan hydrochloride, leucovorin calcium
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
74
States / cities
Scottsdale, Arizona • Duarte, California • Palo Alto, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Jul 24, 2026, 5:26 AM EDT
Terminated Phase 2 Interventional Results available

Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study

NCT04066894
View directory record Official record
Conditions
Low Anterior Resection Syndrome, Malignant Anal Neoplasm, Malignant Bladder Neoplasm, Malignant Cervical Neoplasm, Malignant Ovarian Neoplasm, Malignant Pelvic Neoplasm, Malignant Prostate Neoplasm, Malignant Uterine Neoplasm, Malignant Vaginal Neoplasm, Malignant Vulvar Neoplasm, Rectal Carcinoma
Interventions
Explantation, Quality-of-Life Assessment, Questionnaire Administration, Sacral Nerve Stimulator, Sacral Nerve Stimulator Battery, Therapeutic Conventional Surgery
Procedure · Other · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Houston, Texas • Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jul 24, 2026, 5:26 AM EDT